Posts in Company news

by gene001web
February 9, 2023

GeneTether Therapeutics Inc. Announces Commencement of Strategic Review Process

Vancouver, British Columbia – February 08, 2023
0
read more
by gene001web
November 29, 2022

GeneTether Therapeutics Inc. Announces Third Quarter 2022 Financial Results and Reports on Corporate Highlights

Vancouver, British Columbia – November 25, 2022
0
read more
by gene001web
October 26, 2022

GeneTether Therapeutics Inc. Update – From the Desk of the CEO

Vancouver, British Columbia – October 25, 2022
0
read more
by gene001web
August 25, 2022

GeneTether Therapeutics Inc. Announces Second Quarter 2022 Financial Results and Reports on Corporate Highlights

Vancouver, British Columbia – August 24, 2022
0
read more
by gene001web
May 27, 2022

GeneTether Therapeutics Announces Issuance of New US Composition of Matter Patent for its Innovative Platform Technology Focused on Gene Editing Efficiency

San Lorenzo, California and Vancouver, British Columbia – May 25, 2022
0
read more
by gene001web
May 27, 2022

GeneTether Therapeutics Inc. Announces First Quarter 2022 Financial Results and Reports on Corporate Highlights

Vancouver, British Columbia – May 26, 2022
0
read more
by gene001web
May 9, 2022

GeneTether Therapeutics Inc. Announces Fiscal Year 2021 Financial Results and Reports on Corporate Highlights

Vancouver, British Columbia – April 28, 2022
0
read more
by gene001web
March 29, 2022

GeneTether Therapeutics Completes Initial Public Offering and Announces Listing on the Canadian Securities Exchange

Kelowna, British Columbia – March 29, 2022
0
read more
by gene001web
March 22, 2022

GeneTether Therapeutics Inc. Files Final Prospectus for Initial Public Offering of Units

Vancouver, British Columbia – March 22, 2022
0
read more
by gene001web
March 14, 2022

GeneTether Therapeutics Inc. Receives Notice of Allowance from USPTO

Vancouver, British Columbia – February 14, 2022
0
read more